Severe Bacterial Non-AIDS Infections in Persons With Human Immunodeficiency Virus: The Epidemiology and Evolution of Antibiotic Resistance Over an 18-Year Period (2000-2017) in the ANRS CO3 AquiVih-Nouvelle-Aquitaine Cohort.
Humans
Anti-Bacterial Agents
/ pharmacology
Trimethoprim, Sulfamethoxazole Drug Combination
HIV
Staphylococcus aureus
Prospective Studies
Drug Resistance, Bacterial
Bacteria
Enterobacteriaceae
Escherichia coli
Staphylococcal Infections
/ drug therapy
Fluoroquinolones
Amoxicillin-Potassium Clavulanate Combination
Acquired Immunodeficiency Syndrome
/ drug therapy
Bacteremia
/ epidemiology
Microbial Sensitivity Tests
beta-Lactamases
HIV
antibiotic resistance
morbidity
severe bacterial infections
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
24 05 2023
24 05 2023
Historique:
received:
13
05
2022
medline:
26
5
2023
pubmed:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
Severe non-AIDS bacterial infections (SBIs) are among the leading causes of hospital admissions among persons with human immunodeficiency virus (PWH) in regions with high antiretroviral therapy coverage. This large prospective cohort study of PWH examined the types of infections, bacterial documentation, and evolution of antibiotic resistance among PWH hospitalized with SBIs over an 18-year period. Between 2000 and 2017, 459 PWH had at least 1 SBI with bacterial documentation. Among the 847 SBIs, there were 280 cases of bacteremia, 269 cases of pneumonia, and 240 urinary tract infections. The 1025 isolated bacteria included Enterobacteriaceae (n = 394; mainly Escherichia coli), Staphylococcus aureus (n = 153), and Streptococcus pneumoniae (n = 82). The proportion of S. pneumoniae as the causative agent in pneumonia and bacteremia decreased sharply over time, from 34% to 8% and from 21% to 3%, respectively. The overall antibiotic resistance of S. aureus and S. pneumoniae decreased progressively but it increased for Enterobacteriaceae (from 24% to 48% for amoxicillin-clavulanate, from 4% to 18% for cefotaxime, and from 5% to 27% for ciprofloxacin). Cotrimoxazole prophylaxis was associated with higher nonsusceptibility of S. pneumoniae to amoxicillin and erythromycin, higher nonsusceptibility of Enterobacteriaceae to β-lactams and fluoroquinolones, and a higher risk of extended-spectrum β-lactamase-producing Enterobacteriaceae. The bacterial resistance pattern among PWH between 2014 and 2017 was broadly similar to that in the general population, with the exception of a higher resistance profile of Enterobacteriaceae to fluoroquinolones. The use of cotrimoxazole as prophylaxis was associated with an increased risk of antibiotic resistance.
Sections du résumé
BACKGROUND
Severe non-AIDS bacterial infections (SBIs) are among the leading causes of hospital admissions among persons with human immunodeficiency virus (PWH) in regions with high antiretroviral therapy coverage.
METHODS
This large prospective cohort study of PWH examined the types of infections, bacterial documentation, and evolution of antibiotic resistance among PWH hospitalized with SBIs over an 18-year period.
RESULTS
Between 2000 and 2017, 459 PWH had at least 1 SBI with bacterial documentation. Among the 847 SBIs, there were 280 cases of bacteremia, 269 cases of pneumonia, and 240 urinary tract infections. The 1025 isolated bacteria included Enterobacteriaceae (n = 394; mainly Escherichia coli), Staphylococcus aureus (n = 153), and Streptococcus pneumoniae (n = 82). The proportion of S. pneumoniae as the causative agent in pneumonia and bacteremia decreased sharply over time, from 34% to 8% and from 21% to 3%, respectively. The overall antibiotic resistance of S. aureus and S. pneumoniae decreased progressively but it increased for Enterobacteriaceae (from 24% to 48% for amoxicillin-clavulanate, from 4% to 18% for cefotaxime, and from 5% to 27% for ciprofloxacin). Cotrimoxazole prophylaxis was associated with higher nonsusceptibility of S. pneumoniae to amoxicillin and erythromycin, higher nonsusceptibility of Enterobacteriaceae to β-lactams and fluoroquinolones, and a higher risk of extended-spectrum β-lactamase-producing Enterobacteriaceae.
CONCLUSIONS
The bacterial resistance pattern among PWH between 2014 and 2017 was broadly similar to that in the general population, with the exception of a higher resistance profile of Enterobacteriaceae to fluoroquinolones. The use of cotrimoxazole as prophylaxis was associated with an increased risk of antibiotic resistance.
Identifiants
pubmed: 36610063
pii: 6968505
doi: 10.1093/cid/ciac978
doi:
Substances chimiques
Anti-Bacterial Agents
0
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Fluoroquinolones
0
Amoxicillin-Potassium Clavulanate Combination
74469-00-4
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1814-1821Investigateurs
P Bellecave
(P)
P Blanco
(P)
F Bonnet
(F)
S Bouchet
(S)
D Breilh
(D)
C Cazanave
(C)
S Desjardin
(S)
V Gaborieau
(V)
A Gimbert
(A)
M Hessamfar
(M)
L Lacaze-Buzy
(L)
D Lacoste
(D)
M E Lafon
(ME)
S Lawson-Ayayi
(S)
E Lazaro
(E)
O Leleux
(O)
F Le Marec
(FL)
G Le Moal
(GL)
D Malvy
(D)
L Marchand
(L)
P Mercié
(P)
D Neau
(D)
I Pellegrin
(I)
A Perrier
(A)
V Petrov-Sanchez
(V)
M O Vareil
(MO)
L Wittkop
(L)
N Bernard
(N)
F Bonnet
(F)
D Bronnimann
(D)
H Chaussade
(H)
D Dondia
(D)
P Duffau
(P)
I Faure
(I)
M Hessamfar
(M)
P Mercié
(P)
P Morlat
(P)
E Mériglier
(E)
F Paccalin
(F)
E Riebero
(E)
C Rivoisy
(C)
M A Vandenhende
(MA)
L Barthod
(L)
C Cazanave
(C)
F A Dauchy
(FA)
A Desclaux
(A)
M Ducours
(M)
H Dutronc
(H)
A Duvignaud
(A)
J Leitao
(J)
M Lescure
(M)
D Neau
(D)
D Nguyen
(D)
D Malvy
(D)
T Pistone
(T)
M Puges
(M)
G Wirth
(G)
C Courtault
(C)
F Camou
(F)
C Greib
(C)
E Lazaro
(E)
J L Pellegrin
(JL)
E Rivière
(E)
J F Viallard
(JF)
Y Imbert
(Y)
M Thierry-Mieg
(M)
P Rispal
(P)
O Caubet
(O)
H Ferrand
(H)
S Tchamgoué
(S)
S Farbos
(S)
M O Vareil
(MO)
H Wille
(H)
K Andre
(K)
L Caunegre
(L)
Y Gerard
(Y)
F Osorio-Perez
(F)
I Chossat
(I)
G Iles
(G)
Y Gerard
(Y)
M Labasse-Depis
(M)
F Lacassin
(F)
A Barret
(A)
C Courtault
(C)
B Castan
(B)
J Koffi
(J)
N Rouanes
(N)
A Saunier
(A)
J B Zabbe
(JB)
G Dumondin
(G)
V Gaborieau
(V)
Y Gerard
(Y)
G Beraud
(G)
G Le Moal
(GL)
M Catroux
(M)
M Garcia
(M)
V Giraud
(V)
J P Martellosio
(JP)
F Roblot
(F)
T Pasdeloup
(T)
A Riché
(A)
M Grosset
(M)
S Males
(S)
C Ngo Bell
(CN)
T Pasdeloup
(T)
P Blanco
(P)
I Pellegrin
(I)
C Carpentier
(C)
I Pellegrin
(I)
P Bellecave
(P)
M E Lafon
(ME)
C Tumiotto
(C)
S Bouchet
(S)
D Breilh
(D)
G Miremeont-Salamé
(G)
D Arma
(D)
G Arnou
(G)
M J Blaizeau
(MJ)
P Camps
(P)
M Decoin
(M)
S Delveaux
(S)
F Diarra
(F)
L Gabrea
(L)
S Lawson-Ayayi
(S)
E Lenaud
(E)
D Plainchamps
(D)
A Pougetoux
(A)
B Uwamaliya
(B)
K Zara
(K)
V Conte
(V)
M Gapillout
(M)
O Leleux
(O)
A Perrier
(A)
A Peyrouny-Mazeau
(A)
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. F. B. reports grants or contracts from Gilead for the ANRS CO3 AquiVih Cohort study; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Gilead, MSD, and ViiV Healthcare; and support for attending meetings and/or travel from Gilead, MSD, and ViiV Healthcare. S. P. reports support for conference attendance from bioMérieux and support for attending meetings and/or travel from Roche Diagnostics. A. S. reports support for attending conference from Gilead Sciences and ViiV Healthcare. M.-A. V. reports support for attending conference from Gilead. L. W. reports grants or contracts unrelated to this work from ANRS-MIE (paid to institution). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.